Skip to main content
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics — Investor Relations & Filings

Ticker · MLTX ISIN · KY61559X1045 US Manufacturing
Open in API
Filings indexed 284 across all filing types
Latest filing 2022-03-14 Regulatory Filings
Country US United States of America
Listing US MLTX

About MoonLake Immunotherapeutics

https://moonlaketx.com/

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company that develops therapies for inflammatory and immunologic diseases by leveraging Nanobody® technology. The company's lead investigational asset is sonelokimab, a Nanobody designed to target key inflammatory pathways. MoonLake is advancing sonelokimab through late-stage clinical development, with Phase 3 programs (VELA and IZAR) underway for the treatment of hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). The company focuses on addressing conditions with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
AMENDMENT NO. 2 TO FORM S-1
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 2 to a Form S-1 Registration Statement filed with the SEC by Helix Acquisition Corp. It is a registration statement under the Securities Act of 1933, related to the resale of shares in connection with a business combination. The text includes detailed information about the registration, indemnification of directors and officers, recent sales of unregistered securities, and a list of exhibits. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a proxy statement or voting results. It is a regulatory filing related to securities registration and compliance. The document length is substantial (15,000 characters), and it contains detailed regulatory information rather than a report or announcement of a report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-03-14 English
REGISTRATION STATEMENT
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 1 to Form S-1 Registration Statement filed with the SEC, which is a registration statement under the Securities Act of 1933. It relates to the registration of resale of shares in connection with a business combination and PIPE shares. The document is a preliminary prospectus and registration statement, not a financial report or earnings release. It is a regulatory filing related to securities registration and offering, not an annual report, audit report, or other financial statement. The document is lengthy (15,000 characters) and contains detailed legal and offering information typical of SEC registration statements. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and filing that does not fit into other specific categories like Annual Report or Earnings Release.
2022-03-08 English
PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a definitive proxy statement filed on Schedule 14A with the SEC, as indicated by the header and the text. It is related to an extraordinary general meeting of shareholders of Helix Acquisition Corp. The document discusses the business combination agreement, voting matters, share structure changes, and other shareholder-related proposals. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document is not an annual report, earnings release, or other financial report but rather a solicitation for shareholder votes and related information. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length and content confirm it is the actual proxy statement, not just an announcement of its publication.
2022-03-04 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 20, 2022, by Helix Acquisition Corp. It details the entry into a material definitive agreement, specifically a Convertible Loan Agreement related to a business combination with MoonLake Immunotherapeutics AG. The document includes detailed descriptions of the loan terms, parties involved, and forward-looking statements. It is not a full annual or quarterly report, nor is it a proxy statement or voting results announcement. It is a current report disclosing a material event or transaction. Therefore, it fits the category of a Regulatory Filing (RNS) as a current report under Form 8-K, which is a general regulatory announcement that does not fit other more specific categories.
2022-02-25 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Helix Acquisition Corp. It details the entry into a material definitive agreement, specifically a Convertible Loan Agreement related to a business combination with MoonLake Immunotherapeutics AG. The document includes detailed descriptions of the agreement terms, parties involved, and forward-looking statements. It is not an annual or quarterly report, nor is it a proxy statement or voting results announcement. It is a regulatory filing disclosing a material event (entry into a definitive agreement) as required by SEC rules. The document is substantive and not merely an announcement or certification. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2022-02-25 English
ANNUAL REPORT
Annual Report FY 2021
2022-02-17 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.